Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE:SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology.

Under the agreement, Gannet BioChem will support development activities for SER-252, Serina's investigational therapy for advanced Parkinson's disease. SER-252 recently received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application, enabling the advancement of the program into clinical development.

The collaboration brings together Serina's proprietary POZ Platform™ technology and Gannet BioChem's expertise in process development, scale-up, and manufacturing support for complex therapeutic programs.